Highest-materiality recent filing
Verastem adds up to $75M Revenue Notes; $50M tranche set for Aug 28, 2026
Amendment No. 3 creates new Revenue Notes series (up to $75M) replacing conditional $25M and $50M Initial Note tranches.
Verastem Q2 net product revenue $25.1M; cash runway extended into H2 2027 via $75M Oberland deal
Net product revenue of $25.1M from AVMAPKI FAKZYNJA CO-PACK, up from $2.1M in Q2 2025.
Verastem's VS-7375 shows 93% CA19-9 reduction in PDAC; plans Phase 3 in 1H2027
93% (13/14) of heavily pretreated mPDAC patients at 900mg QD achieved >50% reduction in CA19-9; all remain on treatment.
Verastem reports 86% 6-month OS rate in RAMP 205 pancreatic cancer trial; starts VS-7375 Phase 2
6-month OS rate 86%, ORR 52%, and 83% tumor shrinkage in RAMP 205 RP2D cohort (n=29).
Verastem shareholders elect three Class II directors, approve equity plans at 2026 annual meeting
Michael Bailey, Brian Stuglik, Karin Tollefson elected Class II directors; each received over 51M votes for.
Verastem posts updated corporate presentation on RAS/MAPK pipeline; no new financial data
Corporate presentation dated May 7, 2026, furnished as Exhibit 99.1.
Corporate presentation dated March 4, 2026, furnished as Exhibit 99.1 to Form 8-K.
Verastem reports preliminary 2025 product revenue $30.9M; cash runway to H1 2027
Preliminary AVMAPKI FAKZYNJA CO-PACK net revenue: Q4 2025 ~$17.5M, full year 2025 ~$30.9M (launch from May 2025).
Verastem provides pipeline update; Q3 net product revenue $11.2M; cash runway into 1H2027
AVMAPKI FAKZYNJA CO-PACK launch momentum: $11.2M net product revenue Q3 2025, 133 prescribers.
Verastem discontinues RAMP 203 (KRAS G12C) trial; pivots to VS-7375 for KRAS G12D
Discontinues RAMP 203 (KRAS G12C) trial in advanced NSCLC; focuses on VS-7375 (KRAS G12D inhibitor).
John Johnson appointed chairman of board; Michael Kauffman, MD, PhD, becomes president of development, leaving lead director role.
Verastem raises ~$96.9M in public offering of common stock and pre-funded warrants
Offering includes 8,543,794 firm shares and 3,870,000 pre-funded warrants at $7.25/share; underwriters exercised full option for 1,862,069 additional shares.
Verastem posts $11.2M Q3 product revenue, GAAP net loss $98.5M
AVMAPKI FAKZYNJA CO-PACK achieved $11.2 million net product revenue in first full quarter of launch.
Verastem reports VS-7375 clears first two doses with tumor reduction in 4/5 evaluable patients
No DLTs at 400 mg QD and 600 mg QD; no nausea/vomiting/diarrhea > Grade 1.
Verastem partner reports 41% ORR for VS-7375 in heavily pre-treated KRAS G12D PDAC at ESMO 2025
ORR of 41% (24/59) in heavily pre-treated advanced KRAS G12D PDAC at 600 mg daily; DCR 96.7%.
Verastem reports $2.1M net product revenue from AVMAPKI FAKZYNJA launch in first 6 weeks
AVMAPKI FAKZYNJA co-pack approved May 8, 2025 for KRAS-mutant recurrent LGSOC; $2.1M net revenue in first six weeks.
Verastem's partner reports 68.8% ORR for VS-7375 in KRAS G12D NSCLC at RP2D
ORR of 68.8% (11/16) and DCR of 93.8% (15/16) at recommended Phase 2 dose of 600 mg QD in NSCLC patients.
Verastem reports 52% ORR in PDAC and 42% ORR in NSCLC for KRAS G12D inhibitor VS-7375
Phase 1 data from China: 23 PDAC patients had 52% ORR and 100% DCR; 12 NSCLC patients had 42% ORR and 83% DCR.
Verastem reports 83% ORR in RAMP 205 PDAC trial; details VS-7375 KRAS G12D inhibitor
FDA approved avutometinib + defactinib (AVMAPKI/FAKZYNJA) on May 8, 2025 for KRAS-mutated recurrent LGSOC.
Verastem reports 83% ORR for avutometinib+defactinib in front-line metastatic PDAC
Dose level 1 (RP2D) achieved 83% ORR (10/12 partial responses) in RAMP 205 trial of frontline metastatic pancreatic cancer.
FDA approves Verastem's AVMAPKI FAKZYNJA for KRAS-mutated recurrent LGSOC
First-ever FDA-approved treatment for KRAS-mutated recurrent LGSOC; accelerated approval based on Phase 2 RAMP 201.
Verastem raises $75M private placement for ovarian cancer drug launch and R&D
Gross proceeds of ~$75M from sale of 3.43M shares at $7.00 and 7.29M pre-funded warrants at $6.9999.
Verastem updates pipeline; PDUFA June 30, 2025 for avutometinib+defactinib in LGSOC
PDUFA action date June 30, 2025 for NDA of avutometinib+defactinib in KRAS mutant recurrent LGSOC; launch prep underway.
Verastem exercises option for exclusive ex-Asia rights to KRAS G12D inhibitor VS-7375
Exercised GenFleet option on Jan 14, 2025 for VS-7375, an oral, selective KRAS G12D (ON/OFF) inhibitor.
Verastem appoints Matthew E. Ros as COO effective Jan 14, 2025
Matthew E. Ros appointed Chief Operating Officer; reports to CEO Daniel W. Paterson.
Verastem secures up to $150M from Oberland Capital, repays Oxford loan, NDA accepted with June PDUFA
Initial $75M notes issued; net proceeds~$32.3M after repaying $42.7M Oxford loan; interest-only 6 years.
Verastem reports 31% ORR with avutometinib/defactinib in RAMP 201; NDA submission ongoing
Confirmed ORR of 31% overall (44% KRAS mutant, 17% KRAS wild type) by BICR.
Verastem raises ~$51.1M in underwritten offering of common stock and warrants
13.3M shares of common stock and 13.3M warrants offered at $3.00 per combined unit.
Verastem initiates rolling NDA for avutometinib/defactinib; RAMP 201 median duration 9 months
Rolling NDA for avutometinib+defactinib in recurrent KRAS mutant LGSOC started May 2024; priority review requested.
Verastem initiates rolling NDA for avutometinib+defactinib in recurrent LGSOC; ORR 27%
Rolling NDA submission for avutometinib + defactinib in recurrent LGSOC started H2 2024; potential FDA approval in 2025.
Verastem initiates rolling NDA to FDA for avutometinib/defactinib in KRAS mutant LGSOC
Rolling submission of NDA seeking accelerated approval for recurrent KRAS mt LGSOC; initial sections include nonclinical and quality.
83% (5/6) confirmed partial response in dose level 1 cohort; dose cleared after one DLT.
Verastem outlines NDA filing plan for avutometinib/defactinib in LGSOC by H1 2024; cash $137.1M
Topline data from RAMP 201 trial of avutometinib + defactinib in LGSOC expected H1 2024; rolling NDA for accelerated approval to commence same period.
Verastem outlines 2024 priorities: NDA submission for avutometinib/defactinib in LGSOC in H1 2024
Plans to begin rolling NDA submission for accelerated approval of avutometinib/defactinib in recurrent LGSOC in H1 2024; potential commercial launch in 2025.
Verastem stockholders approve option exchange at special meeting
Stockholders approved one-time exchange of certain stock options held by executive officers, employees, and non-employee directors.
Verastem extends Term C Loan draw deadline by one year to March 2025
Extended outside date for Term C Loan draw from March 31, 2024 to March 31, 2025.
Verastem appoints Daniel Calkins as permanent CFO; $300K salary + 25K stock option
Daniel Calkins appointed CFO effective Oct 24, 2023, after serving as interim since Oct 31, 2022.
Verastem reports 42% ORR in FRAME study for avutometinib/defactinib in LGSOC
Overall response rate 42% (11/26) in evaluable recurrent LGSOC patients.
Verastem posts corporate presentation; content not fully disclosed in filing
Corporate presentation posted on Verastem website on September 12, 2023, furnished as Exhibit 99.1.
Verastem enters CEO employment agreement with Daniel Paterson; $600K salary, equity grants
Daniel Paterson appointed President & CEO effective Aug 1, 2023; employment agreement signed Aug 2, 2023.
Verastem Oncology CEO Stuglik retires; President Paterson appointed CEO effective Aug 1
CEO Brian Stuglik retires effective July 31, 2023; receives $421,850 cash bonus.
Verastem raises ~$97.8M in underwritten offering of common stock and pre-funded warrants
Offering includes 7,181,409 shares at $9.75, 1,538,591 pre-funded warrants at $9.749, and underwriters' option for 1,308,000 shares exercised in full.
Verastem shows 45% ORR in LGSOC at ASCO; plans accelerated filing
Updated RAMP 201 Part A: confirmed ORR 45% in recurrent LGSOC; 86% tumor shrinkage.
Verastem effects 1-for-12 reverse stock split to meet Nasdaq price requirement
Reverse stock split effective 5:00 p.m. ET May 31, 2023; trading on split-adjusted basis June 1 under VSTM.
Verastem reports 45% ORR for avutometinib+defactinib in RAMP 201 LGSOC trial
Combination achieved 45% ORR (13/29 evaluable) and tumor shrinkage in 86% of heavily pretreated LGSOC patients.
Verastem shareholders approve reverse stock split ratio 1:10-30, elect three Class II directors
Elected Robert Gagnon, Brian Stuglik, and Karin Tollefson as Class II directors until 2026 annual meeting.
Verastem draws $15M Term B Loan from Oxford Finance facility
Drew $15M Term B Loan on March 22, 2023, after receiving at least $50M in equity proceeds.
Verastem reports $2M deposit at Silicon Valley Bank; depositors fully protected by FDIC
Company had ~$2 million on deposit at SVB when FDIC took control.
Verastem reports $87.9M cash; secures $30M preferred stock and $15M loan for pipeline
Preliminary unaudited cash and short-term investments of $87.9M as of Dec 31, 2022.
First tranche: 1.2M shares of Series B convertible preferred at $25/share, gross proceeds $30M, closing Jan 27, 2023.
Effective January 14, 2025, Verastem, Inc. (the “Company”) appointed Matthew E. Ros as Chief Operating Officer of the Company.
On October 24, 2023, the board of directors (the “Board”) of Verastem, Inc. (the “Company”) appointed Daniel Calkins as Chief Financial Officer of the Company.
Daniel Paterson was appointed to the position of President and Chief Executive Officer of Verastem, Inc. (the “Company”) effective as of August 1, 2023
On July 7, 2023, Brian Stuglik notified Verastem, Inc. (the “Company)” of his decision to retire as Chief Executive Officer of the Company, effective July 31, 2023
Daniel Paterson, 62, the Company’s President and Chief Operating Officer, will be appointed to the position of President and Chief Executive Officer as of the Effective Date.
In connection with his appointment, Mr. Paterson will also be appointed to the Board, to serve as a Class III director.
the board of directors of Verastem, Inc. (the “Company”) unanimously voted to elect Robert Gagnon as a Class II director of the Company, effective December 13, 2022.
On October 19, 2022, the board of directors (the “Board”) of Verastem, Inc. (the “Company”) unanimously voted to elect Anil Kapur as a Class III director of the Company and to serve on the compensation committee of the Board, effective October 20, 2022.
On September 27, 2022, Robert Gagnon notified Verastem, Inc. (the “Company)” of his decision to resign as Chief Business and Financial Officer of the Company, effective October 31, 2022, to pursue other career opportunities.
Effective October 31, 2022, Daniel Calkins, 35, the Company’s VP of Finance, will serve as the Company’s principal financial officer and principal accounting officer on an interim basis.
On March 23, 2022, Tim Barberich, retired from the Board of Directors (the “Board”) of the Company and from all committees of the Board.
On October 22, 2021, the Board unanimously voted to elect Ms. Michelle Robertson as a Class III director of the Company and to serve on the audit committee of the Board as chairperson, effective November 15, 2021.
Max materiality 0.95 · Median 0.70 · Most common event other_material